Oxaltero 100mg Injection

Introduction

Oxaltero, also known by its generic name Oxaliplatin, is a prescription medication used in the treatment of certain types of cancer. It is classified as an antineoplastic agent and belongs to a class of drugs called platinum-based compounds. Oxaltero is available under various brand names.

Uses

Oxaltero is primarily prescribed for the treatment of colorectal cancer, specifically in combination with other chemotherapy medications. It is commonly used in both adjuvant and metastatic settings, meaning it can be given after surgery to prevent cancer recurrence or in advanced stages of the disease.

Dosage and Administration

The dosage of Oxaltero will vary depending on factors such as the patient’s body surface area, overall health, and the specific cancer being treated. It is typically administered intravenously (IV) by a healthcare professional in a clinical setting, such as a hospital or infusion center. The exact dosing schedule and duration of treatment will be determined by the prescribing physician.

Mechanism of Action

Oxaliplatin works by interfering with the DNA synthesis process in cancer cells, ultimately leading to their destruction. It forms covalent bonds with the DNA molecule, causing cross-links and preventing further replication of the cancer cells. This mechanism of action helps to inhibit the growth and spread of the cancerous cells.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, fatigue, numbness or tingling in the hands and feet (peripheral neuropathy), and temporary hair loss. Note that not all patients will experience these side effects, and they may vary in severity.

Serious side effects are less common but may include allergic reactions, severe infusion reactions, blood disorders, liver toxicity, and nerve damage. If any serious side effects occur, seek immediate medical attention.

Drug Interactions

Oxaltero may interact with other medications, including those available over-the-counter or herbal supplements. Inform your healthcare provider about all the medications you are currently taking to avoid potential interactions. Some drugs may increase the risk of side effects or reduce the effectiveness of Oxaltero.

Precautions

Before starting treatment with Oxaltero, discuss any pre-existing medical conditions or allergies with your healthcare provider. Certain medical conditions, such as kidney problems or a history of nerve disorders, may require special monitoring or adjustments in the treatment plan.

Oxaltero should not be used during pregnancy or breastfeeding unless specifically recommended by a healthcare professional, as it may cause harm to the developing fetus or nursing infant.

Storage

Patient Tips

• Follow the prescribed dosing schedule and complete the full course of treatment as recommended by your healthcare provider.
• Report any unexpected or severe side effects to your doctor promptly.
• Take steps to manage common side effects such as nausea and diarrhea, as your healthcare provider may provide medications or suggestions to help alleviate these symptoms.
• Protect your hands and feet from extreme temperatures and take precautions to prevent injury, as peripheral neuropathy may occur with this medication.
• Inform your healthcare provider about any other medications you are taking, including over-the-counter drugs and supplements, to avoid potential drug interactions.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Oxaliplatin 5 mg/ml concentrate for solution for infusion (Health Professionals SmPC) Available at:
• Oxaliplatin (Drugs.com) [Accessed 23 Jun. 2024] (online) Available at:
• oxaliplatin vial (RX) [Accessed 30 Jun. 2024] (online) Available at:
• Oxaliplatin Injection (MedlinePlus) [Accessed 14 Jun. 2024] (online) Available at:
• Shi Y, Niu Y, Yuan Y, Li K, Zhong C, Qiu Z, Li K, Lin Z, Yang Z, Zuo D, Qiu J, He W, Wang C, Liao Y, Wang G, Yuan Y, Li B. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 2023 Apr 6;14(1):1932. doi: 10.1038/s41467-023-37542-5. [Accessed 11 Jun. 2024] Available at: